Ozanimod: Additional Phase II data

Additional data from 103 patients with moderate to severe active UC in the 24-week maintenance period who achieved a clinical response at week 8 in the double-blind, international Phase II TOUCHSTONE trial showed that 21% of patients in the once-daily 1 mg oral ozanimod arm achieved or maintained clinical remission at week 32 vs. 6% of patients in the placebo arm (p=0.0108). Additionally, 51% of patients who received ozanimod achieved or maintained a clinical response at week 32 vs. 20% of patients who received placebo (p=0.0002). Ozanimod also led to mucosal improvement in 32.8% of patients at week 32 vs. 12.3% of patients who received placebo (p=0.0046). Data were presented at the American College of Gastroenterology meeting in Honolulu. ...